Literature DB >> 10508191

Suppressive versus stimulatory effects of allergen/cholera toxoid (CTB) conjugates depending on the nature of the allergen in a murine model of type I allergy.

U Wiedermann1, B Jahn-Schmid, M Lindblad, C Rask, J Holmgren, D Kraft, C Ebner.   

Abstract

Recent reports have demonstrated that feeding small amounts of antigen conjugated to the B subunit of cholera toxin (CTB) suppress immune responses in experimental models of certain T(h)1-based autoimmune diseases. We have established a model of aerosol sensitization leading to T(h)2-mediated allergic immune responses in BALB/c mice. In the present study two different antigens, the dietary antigen ovalbumin (OVA) and the inhalant allergen Bet v 1 (the major birch pollen allergen), chemically coupled to recombinant CTB were tested for their potential to influence T(h)2-like immune responses. Intranasal administration of OVA-CTB prior to sensitization with OVA led to a significant decrease of antigen-specific IgE antibody levels, but a marked increase of OVA-specific IgG2a antibodies as compared to non-pretreated, sensitized animals. Antigen-specific lympho-proliferative responses in vitro were reduced by 65% in the pretreated group; IL-5 and IL-4 production were decreased in responder cells of lungs and spleens of nasally pretreated mice. In contrast, mucosal administration of rBet v 1-CTB conjugates prior to sensitization led to an up-regulation of allergen-specific IgE, IgG1 and IgG2a, increased in vitro lympho-proliferative responses as well as augmented production of IL-5, IL-4, IL-10 and IFN-gamma. Intranasal administration prior to sensitization of unconjugated allergens showed also contrasting effects: OVA could not significantly influence antigen-specific antibody or cytokine production, whereas intranasal pretreatment with unconjugated Bet v 1 suppressed allergen-specific immune responses in vivo and in vitro. These results demonstrated that the two antigens-in conjugated as in unconjugated form-had different effects on the T(h)2 immune responses. We therefore conclude that the tolerogenic or immunogenic properties of CTB-and probably also other antigen-delivery systems-strongly depend on the nature of the coupled antigen-allergen.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10508191     DOI: 10.1093/intimm/11.10.1717

Source DB:  PubMed          Journal:  Int Immunol        ISSN: 0953-8178            Impact factor:   4.823


  8 in total

1.  Cholera toxin B subunit as a carrier molecule promotes antigen presentation and increases CD40 and CD86 expression on antigen-presenting cells.

Authors:  A George-Chandy; K Eriksson; M Lebens; I Nordström; E Schön; J Holmgren
Journal:  Infect Immun       Date:  2001-09       Impact factor: 3.441

2.  Oral tolerance induction by mucosal administration of cholera toxin B-coupled antigen involves T-cell proliferation in vivo and is not affected by depletion of CD25+ T cells.

Authors:  Annie George Chandy; Susanne Hultkrantz; Sukanya Raghavan; Cecil Czerkinsky; Michael Lebens; Esbjörn Telemo; Jan Holmgren
Journal:  Immunology       Date:  2006-07       Impact factor: 7.397

3.  Mouse Models of Asthma: Characteristics, Limitations and Future Perspectives on Clinical Translation.

Authors:  Tolga Akkoc; Liam O'Mahony; Ruth Ferstl; Cezmi Akdis; Tunc Akkoc
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 2.622

4.  Induction of mucosal tolerance with recombinant Hev b 1 and recombinant Hev b 3 for prevention of latex allergy in BALB/c mice.

Authors:  K Hufnagl; B Wagner; B Winkler; K Baier; R Hochreiter; J Thalhamer; D Kraft; O Scheiner; H Breiteneder; U Wiedermann
Journal:  Clin Exp Immunol       Date:  2003-08       Impact factor: 4.330

5.  Allergen-specific immunosuppression by mucosal treatment with recombinant Ves v 5, a major allergen of Vespula vulgaris venom, in a murine model of wasp venom allergy.

Authors:  Birgit Winkler; Caroline Bolwig; Ulla Seppälä; Michael D Spangfort; Christof Ebner; Ursula Wiedermann
Journal:  Immunology       Date:  2003-11       Impact factor: 7.397

Review 6.  The ABC of clinical and experimental adjuvants--a brief overview.

Authors:  Richard Brunner; Erika Jensen-Jarolim; Isabella Pali-Schöll
Journal:  Immunol Lett       Date:  2009-11-04       Impact factor: 3.685

7.  Cholera toxin and its B subunit promote dendritic cell vaccination with different influences on Th1 and Th2 development.

Authors:  Kristina Eriksson; Margareta Fredriksson; Inger Nordström; Jan Holmgren
Journal:  Infect Immun       Date:  2003-04       Impact factor: 3.441

Review 8.  Cholera-like enterotoxins and Regulatory T cells.

Authors:  Christelle Basset; Fatou Thiam; Cyrille Di Martino; John Holton; John D Clements; Evelyne Kohli
Journal:  Toxins (Basel)       Date:  2010-07-06       Impact factor: 4.546

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.